Company intelligence / Profile preview

BioPharm Solutions

Plainsboro, New Jersey, United Statesbiopharmsolutions.com ↗

Ownership: Private
Employees: ~25
Development stage: Preclinical

Overview

BioPharm Solutions has developed two patented drug delivery platforms: sustained-release microspheres and a phase-transition microneedle patch. Their lead asset, JBPOS-0101 targeting mGluRs for CNS indications including Alzheimer’s disease and infantile spasms, has reached Phase 2 trials. The insulin controlled-release microneedle patch is in preclinical or early clinical development; natural interferon alpha program status is pending.

Therapeutic areas: EndocrinologyNeurology
Modalities: ProteinPeptideVaccineAntibody
Industry: Biotech

Beyond the preview

Go deeper on BioPharm Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioPharm Solutions.

Explore the full profile